MSFT 430.59 0.8407% AAPL 222.5 -0.1212% NVDA 119.1 -0.0336% GOOGL 157.46 1.7907% GOOG 158.37 1.8195% AMZN 186.49 -0.2727% META 524.62 -0.1865% AVGO 167.69 1.902% TSLA 230.29 0.2089% TSM 172.5 0.6242% LLY 923.71 -1.2096% V 287.35 0.6938% JPM 204.32 -1.1036% UNH 594.32 1.0027% NVO 137.0 0.2488% WMT 80.6 1.18% LVMUY 134.665 -0.226% XOM 111.15 -0.0719% LVMHF 675.14 0.1691% MA 493.36 0.254%
Last update at 2024-09-13T20:10:00Z
International Flavors & Fragrances Inc. (IFF): Short Sellers Are Buying This Beauty Stock
Sat 07 Sep 24, 11:53 PMAre You Looking for a Top Momentum Pick? Why International Flavors (IFF) is a Great Choice
Fri 06 Sep 24, 04:00 PMWhy Is International Flavors (IFF) Up 9.5% Since Last Earnings Report?
Thu 05 Sep 24, 03:31 PMCasey's Tops on Q1 Earnings Estimates, Records Strong Inside Margin
Thu 05 Sep 24, 03:19 PMEnergizer Gains on Consumer Engagement: Is the Stock Worth Buying?
Wed 04 Sep 24, 02:33 PMInternational Flavors Hits 52-Week High: What's Aiding the Stock?
Tue 03 Sep 24, 04:41 PMInternational Flavors & Fragrances Inc. (IFF): Among Billionaire Carl Icahn’s Top Stock Picks
Mon 02 Sep 24, 10:23 PMEnergizer (ENR) Gains From Project Momentum & Debt Reduction
Mon 19 Aug 24, 02:16 PMInterpreting International Flavors (IFF) International Revenue Trends
Mon 12 Aug 24, 01:15 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -1625.00000M | 354.00M | 441.37M | 557.45M | 447.76M |
| Minority interest | -7.00000M | -9.00000M | 4.14M | 4.39M | 2.48M |
| Net income | -1836.00000M | 270.00M | 363.23M | 455.87M | 337.30M |
| Selling general administrative | 1768.00M | 1749.00M | 966.13M | 876.12M | 707.46M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 4151.00M | 3735.00M | 2085.87M | 2112.75M | 1682.71M |
| Reconciled depreciation | 1179.00M | 1156.00M | 325.36M | 323.33M | 173.79M |
| Ebit | 1090.00M | 585.00M | 566.48M | 665.27M | 623.03M |
| Ebitda | 2269.00M | 1839.00M | 919.61M | 1051.13M | 796.82M |
| Depreciation and amortization | 1179.00M | 1254.00M | 353.13M | 385.87M | 173.79M |
| Non operating income net other | - | 58.00M | 6.69M | 30.40M | -3.56700M |
| Operating income | 1090.00M | 585.00M | 566.48M | 665.27M | 583.88M |
| Other operating expenses | 11387.00M | 11031.00M | 4496.68M | 4442.68M | 3389.76M |
| Interest expense | 336.00M | 289.00M | 131.80M | 138.22M | 132.56M |
| Tax provision | 211.00M | 75.00M | 74.00M | 97.18M | 107.98M |
| Interest income | 336.00M | 289.00M | 131.80M | 137.66M | 118.41M |
| Net interest income | -336.00000M | -289.00000M | -131.80200M | -138.22100M | -132.55800M |
| Extraordinary items | - | - | - | 0.00000M | -32.80000M |
| Non recurring | - | -1.00000M | 3.78M | 2.37M | -1.17700M |
| Other items | - | - | - | - | - |
| Income tax expense | 211.00M | 75.00M | 74.00M | 97.18M | 107.98M |
| Total revenue | 12440.00M | 11656.00M | 5084.24M | 5140.08M | 3977.54M |
| Total operating expenses | 3098.00M | 3110.00M | 1498.30M | 1415.35M | 1094.92M |
| Cost of revenue | 8289.00M | 7921.00M | 2998.37M | 3027.34M | 2294.83M |
| Total other income expense net | -2715.00000M | -231.00000M | -125.11300M | -107.81800M | -7.46900M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -1836.00000M | 279.00M | 307.53M | 424.33M | 359.54M |
| Net income applicable to common shares | -1868.00000M | 270.00M | 363.23M | 455.87M | 337.30M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 35390.00M | 39678.00M | 13555.67M | 13287.41M | 12889.40M |
| Intangible assets | 9082.00M | 10506.00M | 2727.18M | 2851.93M | 3039.32M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1970.00M | 1850.00M | 341.76M | 60.76M | 277.04M |
| Total liab | 17597.00M | 18455.00M | 7135.08M | 6958.82M | 6764.22M |
| Total stockholder equity | 17734.00M | 21118.00M | 6323.03M | 6217.30M | 6043.37M |
| Deferred long term liab | - | 2518.00M | 593.37M | 641.46M | 687.25M |
| Other current liab | -542.00000M | 3001.00M | 1269.57M | 254.32M | 608.29M |
| Common stock | 35.00M | 35.00M | 16.07M | 16.07M | 16.07M |
| Capital stock | 35.00M | 35.00M | 16.07M | 16.07M | 16.07M |
| Retained earnings | 955.00M | 3641.00M | 4156.17M | 4117.80M | 3956.22M |
| Other liab | 2956.00M | 4054.00M | 1452.00M | 1153.30M | 1131.49M |
| Good will | 13355.00M | 16414.00M | 5593.25M | 5497.60M | 5378.39M |
| Other assets | 667.00M | 1383.00M | 717.26M | 315.75M | 288.67M |
| Cash | 493.00M | 715.00M | 656.84M | 606.82M | 648.52M |
| Cash and equivalents | 483.00M | 711.00M | 649.54M | 606.82M | 634.90M |
| Total current liabilities | 3738.00M | 3633.00M | 1903.73M | 1552.19M | 1128.31M |
| Current deferred revenue | 2265.00M | -1532.00000M | -555.68700M | 362.86M | - |
| Net debt | 10477.00M | 10685.00M | 3756.68M | 3815.25M | 3904.54M |
| Short term debt | 597.00M | 632.00M | 634.16M | 424.63M | 48.64M |
| Short long term debt | 597.00M | 632.00M | 634.16M | 384.96M | 48.64M |
| Short long term debt total | 10970.00M | 11400.00M | 4413.52M | 4422.07M | 4553.06M |
| Other stockholder equity | 18913.00M | 18865.00M | 2848.34M | 2800.33M | 2773.31M |
| Property plant equipment | 4861.00M | 4368.00M | 1458.18M | 1386.92M | 1241.15M |
| Total current assets | 7432.00M | 6987.00M | 3059.80M | 2942.54M | 2941.86M |
| Long term investments | 10.00M | 86.00M | - | - | 31.47M |
| Net tangible assets | -4753.00000M | -5822.00000M | -1911.72200M | -2033.18400M | -2302.95300M |
| Short term investments | - | - | - | - | - |
| Net receivables | 1818.00M | 1906.00M | 929.34M | 1024.01M | 937.76M |
| Long term debt | 10373.00M | 10768.00M | 3779.36M | 3997.44M | 4504.42M |
| Inventory | 3151.00M | 2516.00M | 1131.86M | 1123.07M | 1078.54M |
| Accounts payable | 1418.00M | 1532.00M | 555.69M | 510.37M | 471.38M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | 35.00M | 11.88M | 12.24M | 10.42M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -2169.00000M | -1423.00000M | -697.54100M | -716.89400M | -702.22700M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 35.00M | 16.07M | 16.07M | 16.07M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 3641.00M | 4156.17M | 4117.80M | 3956.22M |
| Treasury stock | - | -997.00000M | -1016.94100M | -1022.82400M | -1030.71800M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1150.00M | 1215.00M | 717.26M | 104.55M | 168.20M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 27958.00M | 32691.00M | 10495.87M | 10344.87M | 9947.54M |
| Capital lease obligations | 651.00M | 784.00M | 43.62M | 39.67M | - |
| Long term debt total | 10385.00M | 10768.00M | 3779.36M | 3997.44M | 4504.42M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 745.00M | -18.00000M | -14.59700M | 25.90M | 7.51M |
| Change to liabilities | -57.00000M | 419.00M | 102.08M | 30.73M | 59.09M |
| Total cashflows from investing activities | 745.00M | -18.00000M | -187.46300M | -225.86600M | -5013.23500M |
| Net borrowings | -344.00000M | -606.00000M | -150.63500M | -156.28200M | 2845.52M |
| Total cash from financing activities | -1229.00000M | -1304.00000M | -511.57000M | -505.05700M | 4871.57M |
| Change to operating activities | 17.00M | -40.00000M | 88.86M | -91.37900M | -15.03300M |
| Net income | -1836.00000M | 279.00M | 367.37M | 460.27M | 339.78M |
| Change in cash | -216.00000M | 56.00M | 35.93M | -24.57700M | 280.48M |
| Begin period cash flow | 716.00M | 660.00M | 623.95M | 648.52M | 368.05M |
| End period cash flow | 500.00M | 716.00M | 659.87M | 623.95M | 648.52M |
| Total cash from operating activities | 345.00M | 1437.00M | 714.10M | 698.97M | 436.70M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 1179.00M | 1156.00M | 325.36M | 323.33M | 173.79M |
| Other cashflows from investing activities | 1251.00M | 379.00M | 18.93M | -15.78800M | -4850.65600M |
| Dividends paid | 810.00M | 667.00M | 322.58M | 313.51M | 230.22M |
| Change to inventory | -893.00000M | -363.00000M | 17.92M | -62.12900M | -117.64100M |
| Change to account receivables | -117.00000M | -169.00000M | -60.97900M | -9.46700M | -49.95800M |
| Sale purchase of stock | 0.00000M | -9.00000M | -21.56600M | 0.00000M | -15.47500M |
| Other cashflows from financing activities | 302.00M | 296.00M | 158.44M | -35.26500M | 2238.08M |
| Change to netincome | 2139.00M | 164.00M | -52.36300M | -46.14400M | 51.50M |
| Capital expenditures | 506.00M | 397.00M | 191.79M | 242.05M | 173.42M |
| Change receivables | - | -169.00000M | -60.97900M | 59.55M | -49.95800M |
| Cash flows other operating | - | 235.00M | 14.71M | -66.65000M | -18.98400M |
| Exchange rate changes | - | -59.00000M | 20.86M | 7.38M | -14.56700M |
| Cash and cash equivalents changes | - | 56.00M | 35.93M | -24.57700M | 280.48M |
| Change in working capital | -1073.00000M | -153.00000M | 73.73M | -38.48900M | -128.60300M |
| Stock based compensation | 49.00M | 54.00M | 35.80M | 34.48M | 29.40M |
| Other non cash items | 2320.00M | 337.00M | -20.44300M | -21.34700M | 2.93M |
| Free cash flow | -161.00000M | 1040.00M | 522.30M | 456.92M | 263.28M |
Sector: Basic Materials Industry: Specialty Chemicals
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IFF International Flavors & Fragrances Inc |
0.15 0.14% | 103.59 | 1326.67 | 19.12 | 1.75 | 1.20 | 2.64 | 18.12 |
| LIN Linde plc Ordinary Shares |
1.47 0.31% | 468.81 | 33.77 | 28.90 | 6.56 | 5.42 | 7.03 | 18.92 |
| AIQUY Air Liquide SA ADR |
0.01 0.03% | 37.63 | 29.34 | 24.57 | 3.42 | 3.95 | 3.87 | 15.91 |
| AIQUF L'Air Liquide S.A |
- -% | 188.05 | 29.39 | 24.69 | 3.41 | 3.97 | 3.87 | 15.91 |
| SHW Sherwin-Williams Co |
1.43 0.38% | 375.40 | 33.33 | 27.40 | 3.38 | 20.60 | 3.88 | 21.36 |
International Flavors & Fragrances Inc., together with its subsidiaries, manufactures and sells cosmetic active and natural health ingredients for use in various consumer products in Europe, Africa, the Middle East, Greater Asia, North America, and Latin America. It operates through four segments: Nourish, Scent, Health & Biosciences, and Pharma Solutions. The Nourish segment offers natural and plant-based specialty food ingredients, such as flavor compounds; savory products that includes soups, sauces, meat, fish, poultry, snacks, etc.; beverages, such as juice drinks, carbonated or flavored beverages, spirits, etc.; sweets that includes bakery products, candy, cereal, chewing gum, etc.; and dairy products, such as yogurt, ice cream, cheese, etc. It also provides natural food protection ingredients consist of natural antioxidants and anti-microbials. Its Scent segment provides fragrance compounds, which include fine fragrances comprising perfumes and colognes, as well as consumer fragrances; fragrance ingredients comprising synthetic and natural ingredients that could be combined with other materials to create fragrance and consumer compounds; and cosmetic active ingredients consisting of active and functional ingredients, and delivery systems to support its customers' cosmetic and personal care product lines. The Health & Biosciences segment develops and produces enzymes, food cultures, probiotics, and specialty ingredients for food and non-food applications. Its Pharma Solutions segment produces and sells cellulosics and seaweed-based pharma excipients. The company sells its products primarily to manufacturers of perfumes and cosmetics, hair and other personal care products, soaps and detergents, cleaning products, dairy, meat and other processed foods, beverages, snacks and savory foods, sweet and baked goods, dietary supplements, infant and elderly nutrition, functional food, and pharmaceutical excipients and oral care products. International Flavors & Fragrances Inc. was founded in 1833 and is headquartered
521 West 57th Street, New York, NY, United States, 10019-2960
| Name | Title | Year Born |
|---|---|---|
| Mr. Glenn Robert Richter | Exec. VP & CFO | 1962 |
| Mr. Nicolas Mirzayantz | Pres of Nourish | 1963 |
| Mr. Franklin K. Clyburn Jr. | CEO & Director | 1965 |
| Mr. Ralf Finzel | Exec. VP & Global Operations Officer | NA |
| Ms. Beril Yildiz | Sr. VP & Chief Accounting Officer | 1978 |
| Mr. Vic Verma | Exec. VP & Chief Information Officer | 1969 |
| Mr. Michael DeVeau | Sr. VP and Chief Investor Relations & Communications Officer | 1981 |
| Dr. Jennifer Amy Johnson Ph.D. | Exec. VP & Gen. Counsel | 1975 |
| Ms. Deborah Borg | Chief HR and Diversity, Equity & Inclusion Officer | 1977 |
| Dr. Gregory Yep | Exec. VP and Chief R&D, Global Integrated Solutions & Sustainability Officer | 1965 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...